Skip to search boxSkip to navigationSkip to main content

Which mechanisms of azithromycin resistance are selected when efflux pumps are inhibited?

  • Cláudia Gomes
    ,
  • Sandra Martínez-Puchol
    ,
  • David Durand
    ,
  • Angela Lluque
    ,
  • Susan Mosquito
    ,
  • Theresa J. Ochoa
  • Hospital Clínic – Universitat de Barcelona
    ,
  • Universidad Peruana Cayetano Heredia, Instituto de Medicina Tropical Alexander von Humboldt
    ,
  • School of Public Health, University of Texas
    ,
Research Output:
Contribution to journal
Article
Peer-review

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 307-311 (5 pages)

Journal (Volume, Issue Number)

International Journal of Antimicrobial Agents (Volume 42, Issue 4)

Publication milestones

  • Published - 10/2013

Publication status

Published - 10/2013

ISSN

0924-8579

Publication IDs

  • Scopus: 84884701563
  • PubMed: 23871456

Abstract

The aim of this study was to develop in vitro azithromycin (AZM)-resistant mutants of Escherichia coli and Shigella spp. in the presence of Phe-Arg β-naphthylamide (PAβN) and to observe which AZM resistance mechanisms other than efflux pumps were inhibited by PAβN emerge. The frequency of mutation ranged between <6.32 × 10-10 and 5.22 × 10-7 for E. coli and between <5.32 × 10-10 and 1.69 × 10-7 for Shigella spp. The E. coli mutants showed an increase in the AZM minimum inhibitory concentration (MIC) up to 128-fold, whilst the Shigella spp. mutants presented increases in MIC levels of up to 8-fold. In one mutant, the insertion of nucleotides encoding the amino acid sequence IMPRAS was found in the rplV gene. Increases in OmpW expression were observed in all E. coli mutants compared with their respective parental isolates. The combination of antibiotics and efflux pump inhibitors appears to be a good option to reduce the frequency of mutation in clinical isolates.

Funding Details

Funding: This work was supported by the Agencia Española de Cooperación Internacional al Desarrollo (AECID) [grants nos. D/024648/09 and D/030509/10 ]. JR has a fellowship from the programme I3 of the Instituto de Salud Carlos III (ISCIII, Spain) [grant no. CES11/012 ].
FundersFunding numbers
ISCIII
CES11/012
AECID
D/030509/10, D/024648/09

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Captures
35
Citations
11

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well